EPROTEIN DISCOVERY
LIVE

Serial Number

79381392

Owner

Nuclera Ltd

Attorney

Rebecca Liebowitz

Filing Date

Jul 25, 2023

Add to watchlist:

No watchlists yet
View on USPTO

EPROTEIN DISCOVERY Trademark

Serial Number: 79381392 • Registration: 7741432

EPROTEIN DISCOVERY is a trademark filed by Nuclera Ltd on July 25, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Nuclera Ltd (9 trademarks)

One Vision Park,

Entity Type: 99

Trademark Details

Filing Date

July 25, 2023

Registration Date

April 1, 2025

Published for Opposition

February 11, 2025

Goods & Services

Medical apparatus and instruments used for DNA and RNA testing and analysis and genetic testing, all for medical purposes; apparatus and instruments for DNA and RNA analysis, DNA and RNA sequencing and protein synthesis in the nature of microfluidic chips, microfluidic cartridges, micro-electromechanical chips, bio sensors, and bio-chips for medical and veterinary purposes; apparatus for DNA, RNA, gene and protein synthesis in the nature of microfluidic chips, microfluidic cartridges, micro-electromechanical chips, bio sensors, and bio-chips for medical and veterinary purposes

Scientific laboratory apparatus and instruments, namely, scientific desktop instruments for DNA, RNA, gene and protein synthesis for scientific use; scientific desktop instruments for DNA, RNA, gene and protein synthesis, namely, microfluidic devices; medical laboratory research instruments in the nature of desktop instrument cartridges for use in scientific apparatus in connection with DNA, RNA, gene, cell and protein synthesis and characterization instruments, namely microfluidic devices; semiconductors; semiconductor chips; microchips; bio sensors in the nature of sensor chips for scientific, research or industrial purposes in DNA, RNA, gene and protein synthesis; biochips in the nature of microchips; scientific research and laboratory apparatus, namely, apparatus and instruments for amplifying DNA and RNA, namely, reactors, bioreactors, and laboratory apparatus and instruments for amplifying DNA and RNA using thermocyclers, not for medical purposes; apparatus and instruments for synthesising DNA and RNA, namely, microarrays, scientific desktop instruments, desktop instrument cartridges, semiconductors, semiconductor chips, microchips, bio sensors, and bio-chips, not for medical purposes; scientific research and laboratory apparatus, namely, apparatus and instruments for processing DNA and RNA, namely scientific desktop instruments, desktop instrument cartridges, semiconductors, semiconductor chips, microchips, biosensors, and biochips; computer hardware; recorded computer software, downloadable computer software and bioinformatics software for use in DNA, RNA, gene and protein synthesis in the fields of biotechnology, drug discovery and medical science; all of the foregoing for use in DNA, RNA, gene and protein synthesis in the fields of biotechnology and medical science

Chemical preparations for scientific purposes; chemical preparations, enzymes, gene editing enzymes, oligonucleotides, and proteins for scientific and industrial purposes; genes, DNA and RNA being nucleic acid sequences for scientific and industrial purposes; nucleic acids comprising natural and synthetic nucleotides and oligonucleotides for scientific and industrial purposes; synthetic DNA, synthetic RNA and synthetic genes being nucleic acid sequences for scientific and industrial purposes; synthetic oligonucleotides and synthetic proteins for scientific and industrial use; chemicals, reagents and enzymes for use in the preparation and creation of synthetic DNA, synthetic RNA, synthetic genes being nucleic acid sequences for scientific and industrial purposes; molecular biology research tools in the nature of biological and biochemical reagents; molecular biology research tools in the nature of chemical, biological and biochemical reagents used for the synthesis of DNA, RNA, oligonucleotides, genes and proteins for scientific and industrial purposes

Biological, chemical and biochemical reagents, namely, proteins, and gene editing enzymes, all for medical diagnostic use; synthetic proteins for medical diagnostic use; vaccines

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 1, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 1, 2025 R.PR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 1, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 1, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 1, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 1, 2025 REAP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 11, 2025 NPUB
PUBLISHED FOR OPPOSITION
Feb 11, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 5, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 22, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 2, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 2, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 2, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 2, 2024 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 26, 2024 GNFN
FINAL REFUSAL E-MAILED
Aug 26, 2024 GNFR
FINAL REFUSAL WRITTEN
Aug 26, 2024 CNFR
REFUSAL PROCESSED BY IB
Aug 17, 2024 RFNP
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 5, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 5, 2024 TROA
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Jul 16, 2024 GEAN
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Jul 16, 2024 GEAP
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Jul 16, 2024 EPEN
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Jul 16, 2024 CPEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 25, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 25, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 25, 2024 TROA
REFUSAL PROCESSED BY IB
Apr 2, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 11, 2024 RFCS
REFUSAL PROCESSED BY MPU
Mar 11, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 10, 2024 RFCR
NON-FINAL ACTION WRITTEN
Feb 10, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 5, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 24, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 20, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 19, 2023 REPR